enveric.com (ENVB) - Cash per Single Share

Corporate emblem and logo of Enveric Biosciences (ENVB)

Innovative molecules for psychiatric therapy provide Enveric Biosciences (ENVB) with potential pricing power. The issuer's cash per share confirms this potential, with the metric holding around 1.25. The stability of the business is supported by the humanitarian neutrality of biomedicine, although sanction risks regarding raw material supplies persist. Efficient reserve management helps offset challenges with overseas testing.

Enveric Biosciences Inc (ENVB) - Cash per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for Enveric Biosciences

- market value and analyst target forecast:
- cash position and cash flow details:
Comprehensive company analysis:Enveric Biosciences
Manufactured product of Enveric

Enveric Biosciences focuses on clinical development, where success depends on stable funding. This metric is calculated by dividing the total volume of liquid assets by the number of outstanding shares. Investors use this metric to assess the business's autonomy from macroeconomic fluctuations and GDP. A high value confirms the company's ability to complete research without emergency capital raises. The trend of the cash cushion per share determines the issuer's financial stability horizon.